Neurogene (NGNE) EBT Margin (2018 - 2024)

Neurogene's (NGNE) quarterly EBT Margin came in at 3416.11% in Q2 2024, down 57059.96% on a QoQ basis from 5.98% in Q3 2019.

Analysis

Neurogene (NGNE) EBT Margin (2018 - 2024) Analysis & Trends

Neurogene (NGNE) has 3 years of EBT Margin data on file, last reported at 3416.11% in Q2 2024.

Quarterly EBT Margin changed N/A year-over-year to 3416.11% in Q2 2024, while the trailing twelve-month figure through Jun 2025 was 11637.62% (up 12476.0% YoY) and the FY2024 annual result came in at 20444.32%, changed N/A from the prior year.
EBT Margin retreated to 3416.11% in Q2 2024, from 5.98% in the prior quarter.
In the past five years, EBT Margin ranged from a high of 3416.11% in Q2 2024 to a low of 3416.11% in Q2 2024.

Peer Set

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	EBT Margin (Qtr)
1	Vertex Pharmaceuticals	138.47 Bn	130.62 Bn	2.84 Bn	41.75%
2	Regeneron Pharmaceuticals	85.18 Bn	77.19 Bn	3.93 Bn	35.61%
3	Argenx Se	63.38 Bn	58.19 Bn	1.37 Bn	35.78%
4	Moderna	58.09 Bn	52.95 Bn	52.00 Mn	-528.97%
5	Revolution Medicines	44.33 Bn	44.33 Bn	-	-
6	BeOne Medicines	40.02 Bn	34.92 Bn	1.53 Bn	18.33%
7	Alnylam Pharmaceuticals	35.57 Bn	32.27 Bn	992.69 Mn	13.77%
8	Royalty Pharma	28.45 Bn	27.61 Bn	-	12.09%
9	Insmed	27.48 Bn	26.32 Bn	358.27 Mn	-2.67%
10	Neurogene	864.53 Mn	864.53 Mn	-	-

Historic Data

Download Data